JRD initiates Hana Biosciences at buy

Jefferies Research Department analyst Adam Walsh said he is initiating coverage of Hana Biosciences with a buy rating and an 18-month price target of $16. The positive outlook on Hana's pipeline is supported by proprietary Zensana survey and discussions with several physician investigators and thought leaders. Hana shares will be driven by multiple catalysts over the next 18 months, and Hana has one of the best management teams in the business. Hana is a South San Francisco, Calif.-based biopharmaceutical company. The company's shares were up 3 cents, or 0.34%, at $8.89 on volume of 186,719 shares versus the three-month running average of 204,878 shares. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.